Northwest & Ethical Investments L.P. Has $10 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Northwest & Ethical Investments L.P. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.9% in the 4th quarter, Holdings Channel reports. The fund owned 19,216 shares of the medical research company’s stock after selling 1,876 shares during the period. Northwest & Ethical Investments L.P.’s holdings in Thermo Fisher Scientific were worth $9,997,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. iA Global Asset Management Inc. raised its holdings in Thermo Fisher Scientific by 3.4% in the 4th quarter. iA Global Asset Management Inc. now owns 133,474 shares of the medical research company’s stock valued at $69,437,000 after buying an additional 4,393 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in Thermo Fisher Scientific by 37.1% in the 4th quarter. Teacher Retirement System of Texas now owns 236,140 shares of the medical research company’s stock valued at $122,847,000 after buying an additional 63,911 shares during the last quarter. Algebris UK Ltd bought a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $878,000. Generali Investments Management Co LLC bought a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $2,536,000. Finally, Vinva Investment Management Ltd raised its holdings in Thermo Fisher Scientific by 8.2% in the 4th quarter. Vinva Investment Management Ltd now owns 19,824 shares of the medical research company’s stock valued at $10,285,000 after buying an additional 1,502 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.6 %

NYSE TMO opened at $518.21 on Thursday. The stock has a market capitalization of $195.50 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business’s fifty day moving average is $547.18 and its 200-day moving average is $557.21.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.33%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.41%.

Analysts Set New Price Targets

A number of research firms have weighed in on TMO. Wells Fargo & Company increased their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Citigroup reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Finally, UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $653.23.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.